John M. Leonard - Aug 30, 2021 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Signature
/s/James Basta Attorney-In-Fact
Stock symbol
NTLA
Transactions as of
Aug 30, 2021
Transactions value $
-$17,449,782
Form type
4
Date filed
9/1/2021, 08:21 PM
Previous filing
Aug 25, 2021
Next filing
Mar 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Options Exercise $156K +11.6K +1.62% $13.40 731K Aug 30, 2021 Direct
transaction NTLA Common Stock Options Exercise $396K +27.2K +3.72% $14.58 758K Aug 30, 2021 Direct
transaction NTLA Common Stock Sale -$314K -2.06K -0.27% $152.81 756K Aug 30, 2021 Direct F1, F2
transaction NTLA Common Stock Sale -$359K -2.33K -0.31% $153.66 754K Aug 30, 2021 Direct F1, F3
transaction NTLA Common Stock Sale -$1.15M -7.43K -0.99% $154.98 746K Aug 30, 2021 Direct F1, F4
transaction NTLA Common Stock Sale -$2.42M -15.6K -2.09% $155.70 731K Aug 30, 2021 Direct F1, F5
transaction NTLA Common Stock Sale -$747K -4.76K -0.65% $156.96 726K Aug 30, 2021 Direct F1, F6
transaction NTLA Common Stock Sale -$493K -3.12K -0.43% $157.75 723K Aug 30, 2021 Direct F1, F7
transaction NTLA Common Stock Sale -$414K -2.6K -0.36% $159.18 720K Aug 30, 2021 Direct F1, F8
transaction NTLA Common Stock Sale -$116K -725 -0.1% $159.98 720K Aug 30, 2021 Direct F1, F9
transaction NTLA Common Stock Sale -$34.7K -216 -0.03% $160.69 719K Aug 30, 2021 Direct F1, F10
transaction NTLA Common Stock Options Exercise $552K +37.8K +5.26% $14.58 757K Aug 31, 2021 Direct
transaction NTLA Common Stock Sale -$5.86M -37.8K -5% $155.00 719K Aug 31, 2021 Direct F1
transaction NTLA Common Stock Options Exercise $674K +28.8K +4% $23.46 748K Sep 1, 2021 Direct
transaction NTLA Common Stock Options Exercise $293K +16K +2.14% $18.30 764K Sep 1, 2021 Direct
transaction NTLA Common Stock Sale -$7.6M -44.7K -5.86% $170.00 719K Sep 1, 2021 Direct F1
holding NTLA Common Stock 58.4K Aug 30, 2021 By Trust F11

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Options Exercise $0 -11.6K -5.19% $0.00 213K Aug 30, 2021 Common Stock 11.6K $13.40 Direct F12
transaction NTLA Stock Option (right to buy) Options Exercise $0 -27.2K -17.53% $0.00 128K Aug 30, 2021 Common Stock 27.2K $14.58 Direct F13
transaction NTLA Stock Option (right to buy) Options Exercise $0 -37.8K -29.6% $0.00 90K Aug 31, 2021 Common Stock 37.8K $14.58 Direct F13
transaction NTLA Stock Option (right to buy) Options Exercise $0 -28.8K -100% $0.00* 0 Sep 1, 2021 Common Stock 28.8K $23.46 Direct F14
transaction NTLA Stock Option (right to buy) Options Exercise $0 -16K -58.13% $0.00 11.5K Sep 1, 2021 Common Stock 16K $18.30 Direct F15
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.21 to $153.165, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.22 to $154.13, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.31 to $155.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.31 to $156.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.31 to $157.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.395 to $158.21, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.49 to $159.465, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.56 to $160.40, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.62 to $160.745, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F11 Shares held by the John M. Leonard 2015 Irrevocable Trust.
F12 The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 134,583 shares as of August 30, 2021.
F13 The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 160,000 shares as of August 30, 2021.
F14 The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 31, 2020.
F15 The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 66,458 shares as of September 1, 2021.